← Leaderboards
Lawrence L Leung
Stanford University
$4,934,000
Attributed
$4,934,000
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $404.4K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,934,000 · 2
VA$0 · 4
By mechanism
R01$4,186,354 · 1
T32$747,646 · 1
I01$0 · 3
IS1$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- William H Robinson$16,848,609
- Jason Song$312,926
- Gary K Steinberg$22,141,624
Others in their field
Top investigators on “Thrombin”
- Enrico Di Cera · Washington University$25,990,132
- Athan Kuliopulos · Tufts Medical Center$21,847,000
- Nigel Mackman · Univ Of North Carolina Chapel Hill$19,107,575
- Zaverio M Ruggeri · Scripps Research Institute$18,391,618
- Erik Ian Tucker · Aronora, Inc.$16,899,000
- Alireza R. Rezaie · Saint Louis University$14,423,469
Research focus
ThrombinIn VivoPlayBlood CoagulationCytokineOsteopontinInflammationCellsCarboxypeptidaseProteinsInflammatoryC-TerminalSiteBinding SitesCancer ModelClotting EnzymeResistanceMalignant NeoplasmsGlioblastomaCleaved CellVeteransPhenotypeThrombomodulinAnimals
Grant awards (25)
Monoclonal antibody inhibition of thrombin cleavage of osteopontin as a novel therapeutic to enhance host antitumor immunity and reduce cardiac fibrosis$0
I01 · FY2025 · VA · contact PI
Monoclonal antibody inhibition of thrombin cleavage of osteopontin as a novel therapeutic to enhance host antitumor immunity and reduce cardiac fibrosis$0
I01 · FY2024 · VA · contact PI
Thrombin Cleavage of Osteopontin Suppresses Host-Anti-Tumor Immune Response in Cancer$0
I01 · FY2023 · VA · contact PI
Thrombin Cleavage of Osteopontin Suppresses Host-Anti-Tumor Immune Response in Cancer$0
I01 · FY2022 · VA · contact PI
Thrombin Cleavage of Osteopontin Suppresses Host-Anti-Tumor Immune Response in Cancer$0
I01 · FY2021 · VA · contact PI
Thrombin Cleavage of Osteopontin Suppresses Host-Anti-Tumor Immune Response in Cancer$0
I01 · FY2020 · VA · contact PI
Chemerin, Complement, and Insulin Resistance$0
I01 · FY2018 · VA · contact PI
Chemerin, Complement, and Insulin Resistance$0
I01 · FY2017 · VA · contact PI
Chemerin, Complement, and Insulin Resistance$0
I01 · FY2016 · VA · contact PI
Chemerin, Complement, and Insulin Resistance$0
I01 · FY2015 · VA · contact PI
Techniplast SealSafe Plus Rat Rack System (LAMb)$0
IS1 · FY2015 · VA · contact PI
Cross-talk Between Coagulation, Inflammation, and Immunity$327,512
R01 · FY2013 · HL · contact PI
Cross-talk Between Coagulation, Inflammation, and Immunity$344,025
R01 · FY2012 · HL · contact PI
Cross-talk Between Coagulation, Inflammation, and Immunity$347,500
R01 · FY2011 · HL · contact PI
Cross-talk Between Coagulation, Inflammation, and Immunity$404,432
R01 · FY2010 · HL · contact PI
Functional Mapping and Protein Engineering of Thrombin$380,584
R01 · FY2007 · HL · contact PI
Functional Mapping and Protein Engineering of Thrombin$391,900
R01 · FY2006 · HL · contact PI
Functional Mapping and Protein Engineering of Thrombin$401,279
R01 · FY2005 · HL
Functional Mapping and Protein Engineering of Thrombin$437,230
R01 · FY2004 · HL
TRAINING PROGRAM IN INVESTIGATIVE HEMATOLOGY$262,072
T32 · FY2003 · HL
FUNCTIONAL MAPPING AND PROTEIN ENGINEERING OF THROMBIN$386,709
R01 · FY2002 · HL
TRAINING PROGRAM IN INVESTIGATIVE HEMATOLOGY$253,110
T32 · FY2002 · HL
FUNCTIONAL MAPPING AND PROTEIN ENGINEERING OF THROMBIN$381,581
R01 · FY2001 · HL
TRAINING PROGRAM IN INVESTIGATIVE HEMATOLOGY$232,464
T32 · FY2001 · HL
FUNCTIONAL MAPPING AND PROTEIN ENGINEERING OF THROMBIN$383,602
R01 · FY2000 · HL